GPT and metabolic dysfunction-associated steatotic liver disease: A recent meta‐analysis of six trials with 309 patients found that SGLT‐2i inhibitors can decrease ALT and liver fat content in patients with NAFLD independent of the hypoglycemic effect of SGLT‐2i inhibitors.24